Cleveland BioLabs Reports 2015 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cleveland BioLabs Reports 2015 Financial Results and Development Progress

BUFFALO, NY--(Marketwired - Feb 22, 2016) - Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today reported financial results and development progress for the fourth quarter and year ended December 31, 2015.

Cleveland BioLabs reported a net loss, excluding minority interests, of $(1.4) million for the fourth quarter of 2015, or $(0.13) per share, compared to net income of $11.3 million, or $3.95 per share, for the fourth quarter of 2014. Net loss, excluding minority interests, for full year 2015 was $(12.6) million, or $(1.79) per share, compared to a net income of $1.6 million, or $0.60 per share, for full year 2014. The 2014 periods reported net income due to a $14.2 million gain on the deconsolidation of the Company's joint venture, Incuron LLC. Excluding the gain on the deconsolidation of Incuron, net loss per share for the fourth quarter of 2014 was $(1.02) and net loss per share for full year 2014 was $(4.66).

As of December 31, 2015, the Company had $19.6 million in cash, cash equivalents and short-term investments, which, based on the Company's current operational plan, is expected to fund the Company's operating requirements beyond one year.

Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "The past year was one of significant momentum and accomplishment for CBLI. We strengthened our financial resources through the addition of a $25 million strategic investor and the award of $15.8 million in funding from the Department of Defense Congressionally Directed Medical Research Programs for continued development of entolimod's biodefense indication. We streamlined our corporate structure with the sale of Incuron, while retaining a royalty on Incuron's future success. We achieved several major milestones with our development programs, including the submission of a pre-Emergency Use Authorization (pre-EUA) dossier for entolimod as a radiation countermeasure and presentation of clinical oncology data for entolimod at the 2015 annual meeting of the American Society of Clinical Oncology. And, we commenced or continued clinical studies designed to further substantiate the potential of our Toll-like receptor agonists, entolimod, CBLB612 and Mobilan."

"The pursuit of commercialization for entolimod as a radiation countermeasure remains our top priority," continued Dr. Kogan. "We continue to work with the U.S. Food and Drug Administration to facilitate the review of our pre-EUA dossier. Products with pre-EUA status may be purchased by certain US government stakeholders for stockpiling in the event of a disaster and we believe achievement of this status may also increase interest from foreign governments. We recently initiated a regulatory process with the European Medicines Agency, which has granted entolimod orphan drug designation for the treatment of acute radiation syndrome, and we continue to evaluate other foreign markets."

Other Recent Operational Highlights

  • Studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis were published in Proceedings of the National Academy of Sciences of the United States of America ( PNAS) . The studies presented in the PNAS publication decipher the cascade of cell-signaling events that are triggered by entolimod activation of the TLR5 pathway in the liver. ( http://www.pnas.org/content/early/2016/01/27/...3.full.pdf )
  • Dosing commenced in a Phase 2 clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer who are recommended for surgery. This study is being conducted in the Russian Federation.
  • A Phase 2 clinical study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy started dosing in the Russian Federation.
  • Panacela Labs continued dosing in a Phase 1 study with Mobilan evaluating single injections administered directly into the prostate of patients with prostate cancer. This study is being conducted in the Russian Federation.

All of the studies being conducted in the Russian Federation are supported by development contracts with the Russian Federation Ministry of Industry and Trade, or MPT.

Further Financial Results

Revenue for the fourth quarter of 2015 was $1.3 million compared to $1.4 million for the fourth quarter of 2014. Revenue for full year 2015 was $2.7 million compared to $3.7 million for full year 2014. These decreases are primarily due to the completion of an Incuron research contract with the Skolkovo Foundation in 2014. Other offsetting variances include new revenue from recently awarded Department of Defense contracts, offset by reduced revenue from MPT contracts due largely to variations in the foreign currency exchange rate.

Research and development costs for the fourth quarter of 2015 were $1.9 million compared to $2.8 million for the fourth quarter of 2014. Research and development costs for full year 2015 decreased to $7.1 million compared to $9.7 million for full year 2014. These decreases primarily resulted from the deconsolidation of Incuron and nonrecurring drug production costs for Mobilan, both occurring in 2014. Somewhat offsetting were reductions in entolimod's biodefense program due to the completion and subsequent submission of the pre-EUA dossier in the second quarter of 2015, offset by increases in entolimod's oncology development largely due to the clinical activities commenced in the Russian Federation.

General and administrative costs for the fourth quarter of 2015 were $1.2 million compared to $2.0 million for the fourth quarter of 2014. General and administrative costs for full year 2015 decreased to $6.4 million compared to $8.5 million for full year 2014. Approximately 40% of this net decrease was attributable to the deconsolidation of Incuron, with the remainder primarily attributable to reductions in personnel and outside professional costs.

At December 31, 2015 the Company had approximately 11 million shares of common stock outstanding. In addition, the Company has 343,643 shares of common stock reserved for issuance pursuant to outstanding stock options with a weighted average exercise price of $46.60 and 2.2 million shares of common stock reserved for issuance pursuant to outstanding warrants exercisable at a weighted average price of $13.98.

About Cleveland BioLabs Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com .

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that do not relate strictly to historical or current facts. Words and phrases such as "potential," "may," "future," "will," "plan," "anticipate," "believe," "intend" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the company's future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals or the impact of any laws or regulations applicable to the company, and plans and objectives of management for future operations. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These factors include, among others, the risks inherent in the early stages of drug development and in conducting clinical trials; the company's plans and expectations with respect to future clinical trials and commercial scale-up activities; the company's ability to attract collaborators with development, regulatory and commercialization expertise and the financial risks related to those relationships; the company's ability to comply with its obligations under license agreements; the company's inability to obtain regulatory approval in a timely manner or at all; the commercialization of the company's product candidates, if approved; the company's plans to research, develop and commercialize its product candidates; future agreements with third parties in connection with the commercialization of any approved product; the size and growth potential of the markets for the company's product candidates, and its ability to serve those markets; the rate and degree of market acceptance of the company's product candidates; the company's history of operating losses and the potential for future losses, which may lead the company to not be able to continue as a going concern; regulatory developments in the United States and foreign countries; the performance of the company's third-party suppliers and manufacturers; and the success of competing therapies that are or may become available. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the company's periodic filings with the Securities and Exchange Commission.

   
   
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
         
  December 31,  
  2015   2014  
             
ASSETS  
Current assets:            
  Cash and cash equivalents $ 5,918,424   $ 3,103,969  
  Short-term investments   13,701,273     -  
  Accounts receivable   631,084     267,199  
  Other current assets   442,642     174,179  
    20,693,423     3,545,347  
             
Equipment, net   122,958     244,537  
Restricted cash   37,663     1,699,759  
Other long-term assets   26,560     56,131  
Investment in Incuron, LLC   -     4,268,458  
Total assets $ 20,880,604   $ 9,814,232  
             
LIABILITIES & STOCKHOLDERS' EQUITY  
             
Current liabilities:            
  Accounts payable $ 197,134   $ 1,057,743  
  Accrued expenses   1,584,826     1,804,456  
  Deferred revenue   11,892     156,317  
  Accrued warrant liability   4,048,900     862,074  
  Current portion of note payable   -     2,640,968  
  Current portion of capital lease obligation   -     7,522  
    5,842,752     6,529,080  
             
Long-term debt   -     1,499,050  
Commitments and contingencies   -     -  
             
Total liabilities   5,842,752     8,028,130  
             
Stockholders' equity:            
  Total Cleveland BioLabs, Inc. stockholders' equity/(deficit)   9,888,182     (1,607,397 )
  Noncontrolling interest in stockholders' equity   5,149,670     3,393,499  
  Total stockholders' equity   15,037,852     1,786,102  
Total liabilities and stockholders' equity $ 20,880,604   $ 9,814,232  
             
             
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(unaudited)  
    Quarter ended December 31,     Year to date December 31,  
    2015     2014     2015     2014  
Revenues:                                
  Grants and contracts   $ 1,269,433     $ 1,390,432     $ 2,708,225     $ 3,701,899  
                                 
Operating expenses:                                
  Research and development     1,896,587       2,821,903       7,143,293       9,654,144  
  General and administrative     1,184,391       2,020,159       6,355,962       8,469,690  
    Total operating expenses     3,080,978       4,842,062       13,499,255       18,123,834  
                                 
Loss from operations     (1,811,545 )     (3,451,630 )     (10,791,030 )     (14,421,935 )
                                 
Other income (expense):                                
  Interest and other expense     261,665       (78,942 )     (99,488 )     (1,089,582 )
  Foreign exchange loss     (318,719 )     (705,583 )     (509,513 )     (1,036,459 )
  Gain on deconsolidation of Incuron, LLC     -       14,206,555       -       14,206,555  
  Investment loss provision     (1,060,834 )     -       (1,060,834 )     -  
  Change in value of warrant liability     1,260,775       998,939       (221,915 )     2,662,329  
  Equity in loss of Incuron, LLC     -       (285,542 )     (362,137 )     (285,542 )
    Total other income (expense)     142,887       14,135,427       (2,253,887 )     14,457,301  
                                 
Net income (loss)     (1,668,658 )     10,683,797       (13,044,917 )     35,366  
                                 
Net loss attributable to noncontrolling interests     246,195       587,974       407,280       1,593,738  
                                 
Net income (loss) attributable to Cleveland BioLabs, Inc.   $ (1,422,463 )   $ 11,271,771     $ (12,637,637 )   $ 1,629,104  
                                 
Net income (loss) per share, basic and diluted   $ (0.13 )   $ 3.95     $ (1.79 )   $ 0.60  
                                 
Weighted average number of shares, basic and diluted     10,769,940       2,856,461       7,060,396       2,702,884  
 
 
Non-GAAP Measures:
We define comparable net income (loss) available to common stockholders per share of common stock, basic and diluted as excluding the effect of the one-time gain on the deconsolidation of Incuron LLC and the one-time investment loss provision. This non-GAAP measure may be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. We believe that this adjusted earnings (loss) per share is relevant and useful information for the Company and our investors as it provides a simple method of comparing results of operations between periods, on a per share basis. A calculation of earnings (loss) per share is provided below:
                                 
Net income (loss) per share, basic and diluted, reported above   $ (0.13 )   $ 3.95     $ (1.79 )   $ 0.60  
Investment loss provision     0.10       -       0.15       -  
Gain on deconsoidation of Incuron, LLC     -       (4.97 )     -       (5.26 )
                                 
Comparable Net loss available to common stockholders per share of common stock, basic and diluted   $ (0.03 )   $ (1.02 )   $ (1.64 )   $ (4.66 )
                                 
   
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES       
CONSOLIDATED STATEMENTS OF CASH FLOWS       
         
  For the Year Ended December 31,  
  2015   2014  
     
Cash flows used in operating activities $ (12,080,120 ) $ (14,455,187 )
Cash flows used in investing activities   (10,276,623 )   (1,786,744 )
Cash flows provided by financing activities   24,935,624     10,590,030  
Effect of exchange rate change on cash and cash equivalents   235,574     (1,292,595 )
Increase (decrease) in cash and cash equivalents   2,814,455     (6,944,496 )
Cash and cash equivalents at beginning of period   3,103,969     10,048,466  
Cash and cash equivalents at end of period $ 5,918,424   $ 3,103,969  
             
             

Contact: Rachel Levine Vice President, Investor Relations Cleveland BioLabs, Inc. T: (917) 375-2935 E: rlevine@cbiolabs.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 154

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 34

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming

Updated Category News Views 90

A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 100

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 299

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 59

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 47

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading

Top 5 Most Recently Viewed Articles

Hearth Market Expected to Surpass $14 Billion by 2032

Updated Category News Views 148

Overview of the Hearth Market Recent studies predict that the hearth market value will ascend from USD 9.70 billion in 2023 to an impressive USD 14.14 billion by 2032. This growth reflects a steady compound annual growth rate (CAGR) of 4.3% during this timeframe. The importance of hearths, commonly defined as the floor area in front of a fireplace, extends beyond mere...

Continue Reading
Understanding the IRS's Authority Over Email Seizures

Updated Category News Views 304

The IRS and Electronic Data Seizures In the modern era, questions of privacy and government oversight of electronic communications are more pressing than ever. Specifically, the IRS has a particular framework guiding how it obtains access to electronic records, often bypassing traditional warrant processes. However, the requirement for a search warrant remains intact when...

Continue Reading
United Microelectronics: Insights on Upcoming Earnings Release

Updated Category News Views 130

Upcoming Earnings Report for United Microelectronics United Microelectronics UMC is gearing up for its latest quarterly earnings report. Investors are eager to learn about the company’s financial performance and projections during this critical period. Analysts have made their projections clear, estimating that United Microelectronics will report an earnings per share...

Continue Reading
Stitch Fix Reports Financial Results for Fiscal Year 2025

Updated Category News Views 465

Stitch Fix's Fiscal Year 2025 Financial Overview Stitch Fix, Inc. (NASDAQ: SFIX), the foremost online personal styling service, recently released its financial results for the fiscal year 2025. The performance for Q4 2025 indicates a decrease in net revenue of 2.6% year-over-year; however, there was a 4.4% increase on an adjusted basis that corrects for the extra week in...

Continue Reading
Freight Technologies Unveils Innovative Approach to Crypto Treasury

Updated Category News Views 137

Freight Technologies Makes Bold Steps in Digital Assets Freight Technologies, Inc. (Nasdaq: FRGT), a leading logistics management innovation company, has recently taken significant measures to enhance its digital asset strategy. The company is tapping into the rapidly evolving cryptocurrency market by securing up to USD $20 million through convertible notes. This funding...

Continue Reading